[go: up one dir, main page]

PE20090152A1 - Combinacion farmaceutica que comprende un antagonista del receptor de progesterona y un antiestrogeno - Google Patents

Combinacion farmaceutica que comprende un antagonista del receptor de progesterona y un antiestrogeno

Info

Publication number
PE20090152A1
PE20090152A1 PE2008000687A PE2008000687A PE20090152A1 PE 20090152 A1 PE20090152 A1 PE 20090152A1 PE 2008000687 A PE2008000687 A PE 2008000687A PE 2008000687 A PE2008000687 A PE 2008000687A PE 20090152 A1 PE20090152 A1 PE 20090152A1
Authority
PE
Peru
Prior art keywords
alkyl
group
estra
alkenylene
alkylene
Prior art date
Application number
PE2008000687A
Other languages
English (en)
Inventor
Jens Hoffmann
Daniel Korr
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20090152A1 publication Critical patent/PE20090152A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN: a)11B-(4-ACETILFENIL)-17B-HIDROXI-17A-(1,1,2,2,2-PENTAFLUOROETIL)-ESTRA-4,9-DIEN-3-ONA, O UN ANALOGO; b)UN ANTIESTROGENO PURO, TAL COMO I, DONDE Hal ES F O Cl, Y QUE ESTA UNIDO AL ESQUELETO ESTRATRIENO EN LA POSICION 11B; R3 ES H, (C1-C4)ALQUILO, (C1-C4)ALCANILO O UN (C3-C7)ETER CICLICO CON UN ATOMO DE O; R17' ES H, (C1-C4)ALQUILO O (C1-C4)ALCANILO; R17'' ES (C1-C4)ALQUILO, (C1-C4)ALQUINILO; SK ES EL GRUPO U-V-W-X-Y-Z-E QUE ESTA UNIDO AL ESQUELETO DE ESTRATRIENO A TRAVES DE U EN LA POSICION 7A; U ES (C1-C13)ALQUILENO O -ALQUENILENO; V ES CH2- O C(O); W ES N(R6), UN GRUPO N+(O-)(R6), UN ANILLO N-OXIDO DE AZOLIDINILENO, ENTRE OTROS; R6 ES H, CH2-R7 O C(O)-R7; R7 ES H, (C1-C14)ALQUILO, (C3-C10)CICLOALQUILO, ENTRE OTROS; X ES (C1-C12)ALQUILENO, ALQUENILENO O ALQUINILENO; Y ES UN ENLACE DIRECTO, (C3-C10)CICLOALQUILO, (C7-C20)ARALQUILO, ENTRE OTROS; Z ES UN ENLACE DIRECTO, (C1-C9)ALQUILENO, ALQUENILENO O ALQUINILENO; E ES UN GRUPO CF3 O UN GRUPO ARILO PARCIALMENTE FLORADO; SON SELECCIONADOS 11B-FLUORO-17A-METIL-7A-{5-[METIL-(8,8,9,9,9-PENTAFLUORONONIL)AMINO]PENTIL}-ESTRA-1,3,5(10)-TRIEN-3,17B-DIOL, 7A-[9-(4,4,5,5,5-PENTAFLUOROPENTIL-SULFINIL)-NONIL]-ESTRA-1,3,5(10)-TRIEN-3,17 BETA-DIOL, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON DE UTILIDAD EN EL TRATAMIENTO Y/O PREVENCION DE CANCER GASTRICO, DE MAMA, ENDROMETRIOSIS, MIELOMA, ENTRE OTROS
PE2008000687A 2007-04-23 2008-04-22 Combinacion farmaceutica que comprende un antagonista del receptor de progesterona y un antiestrogeno PE20090152A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07090083 2007-04-23
US91437207P 2007-04-27 2007-04-27

Publications (1)

Publication Number Publication Date
PE20090152A1 true PE20090152A1 (es) 2009-04-30

Family

ID=39671992

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000687A PE20090152A1 (es) 2007-04-23 2008-04-22 Combinacion farmaceutica que comprende un antagonista del receptor de progesterona y un antiestrogeno

Country Status (11)

Country Link
US (1) US20090029954A1 (es)
EP (1) EP2136796A2 (es)
JP (1) JP2010524997A (es)
AR (1) AR066234A1 (es)
CA (1) CA2683809A1 (es)
CL (1) CL2008001148A1 (es)
PA (1) PA8777301A1 (es)
PE (1) PE20090152A1 (es)
TW (1) TW200904451A (es)
UY (1) UY31044A1 (es)
WO (1) WO2008128791A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013131105A1 (en) * 2012-03-02 2013-09-06 Sri International Synergistic anti-proliferation activity of tas-108 with mtor inhibitors against cancer cells
AU2016294185B2 (en) * 2015-07-14 2021-10-14 National University Corporation Tottori University Estrogen receptor β partial agonist having estrogen receptor α inhibitory effect, and therapeutic agent for gynecological disorders using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
PL360151A1 (en) * 2000-10-18 2004-09-06 Schering Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
SI1326617T1 (sl) * 2000-10-18 2007-02-28 Schering Ag Uporaba 11 beta-(4-acetilfenil)-17 beta-hidroksi-17 alfa-(1,1,2,2,2-pentafluoroetil)estra-4,9-dien-3-ona za pripravo zdravila za zdravljenje raka dojk, raka jajcnikov, endometrijskega raka, mieloma in meningioma
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Also Published As

Publication number Publication date
JP2010524997A (ja) 2010-07-22
US20090029954A1 (en) 2009-01-29
WO2008128791A3 (en) 2008-12-11
UY31044A1 (es) 2008-11-28
TW200904451A (en) 2009-02-01
PA8777301A1 (es) 2008-11-19
AR066234A1 (es) 2009-08-05
CA2683809A1 (en) 2008-10-30
EP2136796A2 (en) 2009-12-30
WO2008128791A2 (en) 2008-10-30
CL2008001148A1 (es) 2008-11-03

Similar Documents

Publication Publication Date Title
MX2021011394A (es) Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico.
BRPI0809931B8 (pt) antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo
PE20171185A1 (es) Dimeros de benzodiazepina unidos con puentes de heteroarileno, conjugados de estos, y sus metodos de preparacion y uso
PE20030727A1 (es) 17OALQUIL-17ß-OXI-ESTRATRIENOS, PRODUCTOS INTERMEDIARIOS PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
PE20171184A1 (es) Dimeros de benzodiazepina, conjugados de estos, y sus metodos de preparacion y uso
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
CL2012000166A1 (es) Compuesto (11beta,17beta)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; y su uso para el tratamiento y/o la prevencion de fibroides uterinos, endometriosis, sangrados menstruales severos, meningiomas, cancer de mama hormonodependiente y de trastornos asociados a la menopausia, entre otros.
AR060050A1 (es) Compuestos moduladores del receptor de s1p y uso de los mismos
NO20090578L (no) Farmasoytisk sammensetning inneholdende en tetrahydrofolsyre
BR112016011949A8 (pt) composto, composição farmacêutica, e, uso dos mesmos”
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
PE20130524A1 (es) Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometrosis
PE20181523A1 (es) Tratamiento de lupus nefritis usando laquinimod
ECSP066475A (es) Derivados de tropano
PA8806801A1 (es) Compuestos de amida como refuerzos de antivirales
ZA202400851B (en) Dosing regimens associated with extended release paliperidone injectable formulations
MX2024009188A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
AR049262A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
MX2023006368A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
PE20071019A1 (es) Formulaciones farmaceuticas liquidas y semi-solidas que comprenden un modulador de receptores estrogenicos
PE20160655A1 (es) Profarmacos de formacion de compuestos
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
PE20090152A1 (es) Combinacion farmaceutica que comprende un antagonista del receptor de progesterona y un antiestrogeno
PE20141527A1 (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos
AR044450A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal